Karim Fizazi
Institut Gustave Roussy
770 Papers
3.2K Citations
Karim Fizazi is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 96, co-authored 658 publications. Previous affiliations of Karim Fizazi include Université Paris-Saclay & University College London.
Chat about Author
Papers
Nonfamilial Chronic Serum Alpha-Fetoprotein Increase in a Patient With Clinical Stage I Seminoma.
Clara Vazeille,Christophe Massard,Yohann Loriot,Laurence Albiges,Frédéric Troalen,Bernard Escudier,Karim Fizazi +6 more
TL;DR: The case of a 45-year-old man with pure seminoma and persistently elevated and stable serum AFP levels after orchiectomy without evidence of residual disease is described.
2
Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].
Christophe Massard,Kim N. Chi,Daniel Castellano,Johann S. de Bono,Gwenaelle Gravis,Luc Dirix,Jean-Pascal Machiels,Alain C. Mita,Begoña Mellado,Sabine Turri,Joan Maier,Denes Csonka,Arunava Chakravartty,Karim Fizazi +13 more
2
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.
Karim Fizazi,Albertas Ulys,Lisa Sengeløv,Mette Moe,Sylvain Ladoire,Antoine Thiery Vuillemin,Aude Flechon,Roberto Sabbatini,Joaquim Bellmunt,Miguel Angel Climent,Simon Chowdhury,Herlinde Dumez,Michaela Matouskova,Nicolas Penel,Sigita Liutkauskiene,Lech Stachurski,Cora N. Sternberg,Frederique Baton,Nathalie Germann,Gedske Daugaard +19 more
TL;DR: This study assessed whether TASQ maintenance therapy improved disease control duration in mCRPC pts with response or stabilization on first-line docetaxel (NCT01732549) and found that it did not.
2
Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).
Susan Halabi,Sandipan Dutta,Kim N. Chi,Catherine M. Tangen,Daniel P. Petrylak,John C. Araujo,Karim Fizazi,David I. Quinn,Celestia S. Higano,Ian F. Tannock,Eric J. Small,William Kevin Kelly +11 more
TL;DR: There were no differences in PFS and PSA PFS outcomes in C, AA, or Asian men with mCRPC enrolled on these phase III clinical trials with DP.
2
784 the impact of abiraterone acetate therapy on patient-reported pain and functional status in chemotherapy-naïve patients with progressive, metastatic castration-resistant prostate cancer - results from an updated analysis
Neal D. Shore,Ethan Basch,Charles J. Ryan,Peter F.A. Mulders,Thian Kheoh,Karim Fizazi,Christopher J. Logothetis,Dana E. Rathkopf,Matthew R. Smith,Paul N. Mainwaring,Yanni Hao,Thomas W. Griffin,Susan Li,Michael Meyers,Arturo Molina,Charles S. Cleeland +15 more
2